ClinicalTrials.gg
RecruitingNCT07463885SVALBARDUpdated Oct 15, 2026

Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure

An interventional study of Spontaneous Ventilation Strategy and Controlled Ventilation Strategy in Acute Respiratory Distress Syndrome (ARDS) and Acute Hypoxemic Respiratory Failure, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingFirst site in Norway+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Acute hypoxemic respiratory failure may progress to acute respiratory distress syndrome, a life-threatening condition that often requires mechanical ventilation. The optimal ventilation strategy in this patient population remains uncertain.

The SVALBARD trial is a feasibility and pilot study designed to compare spontaneous versus controlled mechanical ventilation in patients with acute hypoxemia respiratory failure.

The primary objective is to assess the feasibility of the study procedures and interventions, while also collecting descriptive data on key clinical variables to inform the design of a future randomized controlled trial.

Read the detailed description

Acute hypoxemic respiratory failure is a condition that can progress to acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation to support gas exchange and limit lung injury. ARDS guidelines recommend lung-protective ventilation strategies-specifically low tidal volumes and limited airway pressures-to reduce ventilator-induced lung injury. Observational studies, including the global LUNG SAFE project, have described the epidemiology and management of acute hypoxemic respiratory failure and ARDS. These studies report high mortality rates (global hospital mortality, 38.6%) associated with the severity of lung injury rather than strict fulfilment of ARDS criteria. They also reveal variability in the application of evidence-based ventilation strategies across institutions. This inconsistency highlights a barrier to progress: the lack of conclusive evidence guiding ventilation management in patients with acute hypoxemic respiratory failure.

One unresolved issue is the role of spontaneous breathing during mechanical ventilation. Observational studies suggest that allowing spontaneous effort may reduce need for sedation and increase ventilator-free days. In contrast, preclinical models indicate that spontaneous breathing in severe lung injury may worsen outcomes through mechanisms such as patient-ventilator asynchrony and regional overdistension. This contrast underscores the need to balance potential benefits against physiological risks in the absence of adequate trial data. ARDS guidelines do not provide clear recommendations on this issue due to limited evidence. Only one large RCT has compared controlled ventilation to spontaneous breathing modes, finding no difference in short-term outcomes and not assessing long-term endpoints such as cognitive impairment or quality of life.As a result, clinicians must choose between guideline-based controlled ventilation and approaches that incorporate spontaneous breathing, within the context of evolving sedation practices and recovery goals. Given the variability of acute hypoxemic respiratory failure and the current evidence gap, genuine uncertainty ('clinical equipoise') exists regarding the optimal ventilation strategy. This supports the need for well-designed RCTs to determine whether spontaneous ventilation offers clinical benefit or harm. A recent survey of Nordic clinicians showed support for such a trial in patients with moderately severe acute hypoxemic respiratory failure, underscoring the relevance of this research.

The SVALBARD study is a feasibility and pilot trial comparing spontaneous and controlled mechanical ventilation in patients with acute hypoxemic respiratory failure. The study will evaluate whether it is possible to recruit patients, apply the assigned ventilation strategies, and collect the required data in a reliable way.

In addition, the study will collect descriptive clinical data to better understand patient characteristics and outcomes. The results will be used to improve the design and planning of a future randomized controlled trial.

The trial will accrue 80 patients from eight different intensive care units, four in Norway and four in Denmark.

02

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
  • Acute Hypoxemic Respiratory Failure

Keywords

  • Acute respiratory distress syndrome
  • Acute hypoxemic respiratory failure
  • Mechanical ventilation
  • assisted ventilation
  • controlled ventilation
  • feasibility trial
  • randomised clinical trial
03

In context

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

We will include patients who fulfil all the following criteria:

  • Acutely admitted to the ICU
  • AND age ≥ 18 years
  • AND invasive mechanical ventilation via endotracheal tube or tracheostomy for less than 24 hours
  • AND moderate acute hypoxemic respiratory failure, defined as a PaO₂-FiO₂ ratio between 13.3-26.6 kPa (100-200 mmHg) with PEEP ≥ 5 cm H2O, based on arterial blood gas analysis obtained within 2 hours before randomisation.
  • AND new pulmonary infiltrate (uni- or bilateral) on chest x-ray or CT-scan obtained no more than 24 hours before randomisation.

Exclusion criteria

Exclusion Criteria:

  • Previously randomised into the SVALBARD trial.
  • following inclusion expected to be unobtainable
  • Patient under coercive measures
  • Withdrawal from active therapy or brain death deemed imminent.
  • Chronic hypercapnic respiratory failure defined as PaCO2 > 8 kPa (60 mm Hg) in the outpatient setting.
  • Listed for lung transplant.
  • Acute heart failure / acute myocardial infarction / cardiac arrest during or causing index ICU admission.
  • Use of home oxygen.
  • Chronic mechanical ventilation for any reason except for non-invasive mechanical ventilation (CPAP/BIPAP) used solely for sleep apnoea disorder.
  • Currently receiving ECMO therapy.
  • Burns >70 % total body surface.
  • Acute brain injury or stroke (any, including subarachnoid haemorrhage, SAH).
  • Intracranial hypertension.
  • Patients with planned repeat surgical interventions during current stay in ICU.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Spontaneous ventilation

    Invasive mechanical ventilation in which the patient initiates some or all breaths, and the ventilator assists or supports those spontaneous efforts.

    Procedure: Spontaneous Ventilation Strategy

  • Active comparator
    Controlled ventilation

    Invasive mechanical ventilation in which all breaths are delivered by the ventilator, with no patient-initiated respiratory effort.

    Procedure: Controlled Ventilation Strategy

Interventions

  • ProcedureSpontaneous Ventilation Strategy

    Invasive mechanical ventilation strategy allowing spontaneous breathing while receiving ventilatory support from a standard ICU mechanical ventilator.

  • ProcedureControlled Ventilation Strategy

    Invasive mechanical ventilation strategy in which spontaneous respiratory effort is suppressed and breaths are fully delivered by a standard ICU mechanical ventilator.

06

What researchers measure

Primary outcomes

  1. Recruitment Rate

    Proportion of eligible patients who are enrolled in the trial (primary feasibility outcome).

    Time frame: 1 year from trial initiation

Secondary outcomes

  1. Consent Rate

    Proportion of eligible patients who provide informed consent to participate in the trial.

    Time frame: 1 year from trial initiation

  2. Randomisation Rate

    Proportion of consented participants who are randomised.

    Time frame: 1 year from trial initiation

  3. Protocol Adherence

    Proportion of study procedures completed according to protocol requirements.

    Time frame: 1 year from trial initiation

  4. Major Protocol Violations

    Proportion of enrolled participants with at least one major protocol deviation.

    Time frame: 1 year from trial initiation

  5. Retention Rate

    Proportion of randomised participants who complete study follow-up.

    Time frame: 1 year from trial initiation

  6. Time to Completion of Feasibility Study

    Time from trial initiation to completion of feasibility study recruitment and follow-up.

    Time frame: Up to 1 year

  7. Proportion of Participants Achieving Therapeutic Target at 48 Hours

    Proportion of randomised participants achieving the predefined therapeutic target within 48 hours after randomisation.

    Time frame: 48 hours from randomisation

  8. Between-Group Difference in Therapeutic Target Attainment at 48 Hours

    Difference between study groups in the proportion of participants achieving the predefined therapeutic target at 48 hours.

    Time frame: 48 hours

  9. Proportion of Missing Therapeutic Target Data at 48 Hours

    Proportion of randomised participants with missing data for the predefined therapeutic target assessed 48 hours after randomisation.

    Time frame: 48 hours from randomisation

  10. Clinical: All-Cause Mortality at 30 Days

    Proportion of enrolled participants who have died from any cause by 30 days.

    Time frame: 30 days

  11. Clinical: All-Cause Mortality at 90 Days

    Proportion of enrolled participants who have died from any cause by 90 days.

    Time frame: 90 days

  12. Clinical: All-Cause Mortality at 180 Days

    Proportion of enrolled participants who have died from any cause by 180 days.

    Time frame: 180 days

  13. Clinical: Clinical: Days Alive and Free of Life Support at 90 Days

    Number of days alive and free of life support (invasive mechanical ventilation, renal replacement therapy, or vasoactive drug support) from randomisation through day 90. Life support-free days are calculated as the number of calendar days alive and free of all listed life support modalities during the 90-day period. Participants who die before day 90 will be assigned 0 days.

    Time frame: 90 days

  14. Clinical: Days Alive and Out of Hospital at 90 Days

    Number of days alive and out of hospital from randomisation through day 90. Participants who die before day 90 will be assigned 0 days.

    Time frame: 90 days

  15. Clinical: Health-related quality of life (EQ-5D-5L Index Score)

    Health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The index value ranges from less than 0 (health state worse than death) to 1 (best health), with higher scores indicating better health. Participants who die before assessment will be assigned a value of 0.

    Time frame: 180 days

  16. Clinical: Health-Related Quality of Life (EQ-5D Visual Analogue Scale Score)

    Health-related quality of life measured using the EQ-5D Visual Analogue Scale (VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health. Participants who die before assessment will be assigned a value of 0.

    Time frame: 180 days

  17. Clinical: Montreal Cognitive Assessment (MoCA) Score at 180 Days

    Cognitive function assessed using the Montreal Cognitive Assessment (MoCA) Version 2.1 (telephone version). Scores range from 0 to 15, with higher scores indicating better cognitive function. Participants who die before assessment will be assigned a score of 0.

    Time frame: 180 days

  18. Clinical: Impact of Event Scale-6 (IES-6) Score at 180 Days

    Post-traumatic stress symptoms assessed using the Impact of Event Scale-6 (IES-6). The scale consists of six items rated from 0 (not at all) to 4 (extremely). The mean score ranges from 0 to 4, with higher scores indicating more severe post-traumatic stress symptoms.

    Time frame: 180 days

  19. Clinical: Modified Medical Research Council (mMRC) Dyspnea Scale Score at 180 Days

    Dyspnea assessed using the Modified Medical Research Council (mMRC) Dyspnea Scale. Scores range from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house or while dressing/undressing), with higher scores indicating worse dyspnea.

    Time frame: 180 days

  20. Clinical: Chalder Fatigue Questionnaire (CFQ) Score at 180 Days

    Fatigue assessed using the Chalder Fatigue Questionnaire (CFQ), consisting of 11 items scored from 0 to 3. Total scores range from 0 to 33, with higher scores indicating greater fatigue.

    Time frame: 180 days

07

Study locations

1 of 1 sites recruiting
  • Oslo University Hospital - Rikshospitalet
    Oslo, Oslo 0372, Norway
    Recruiting
    • Tayyba N Aslam, MD · Contacttayasl@ous-hf.no · +4798097489
    • Jon H Laake, MD PhD · Contactjlaake@ous-hf.no · +4797660919
    • Tayyba N Aslam, MD · Principal investigator
    • Jon H Laake, MD PhD · Sub investigator
08

References and documents

Publications

  • Aslam TN, Klitgaard TL, Ahlstedt CAO, Andersen FH, Chew MS, Collet MO, Cronhjort M, Estrup S, Fossum OK, Frisvold SK, Gillmann HJ, Granholm A, Gundem TM, Hauss K, Hollenberg J, Huanca Condori ME, Hastbacka J, Johnstad BA, Keus E, Kjaer MN, Klepstad P, Krag M, Kvale R, Malbrain MLNG, Meyhoff CS, Morgan M, Moller A, Pfortmueller CA, Poulsen LM, Robertson AC, Schefold JC, Schjorring OL, Siegemund M, Sigurdsson MI, Sjovall F, Strand K, Stueber T, Szczeklik W, Wahlin RR, Wangberg HL, Wian KA, Wichmann S, Hofso K, Moller MH, Perner A, Rasmussen BS, Laake JH; SVALBARD investigators. A survey of preferences for respiratory support in the intensive care unit for patients with acute hypoxaemic respiratory failure. Acta Anaesthesiol Scand. 2023 Nov;67(10):1383-1394. doi: 10.1111/aas.14317. Epub 2023 Sep 22. PubMed 37737652 ↗
  • Aslam TN, Klitgaard TL, Moller MH, Perner A, Hofso K, Skrubbeltrang C, Rasmussen BS, Laake JH. Spontaneous Versus Controlled Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome-A Scoping Review. Acta Anaesthesiol Scand. 2025 Sep;69(8):e70096. doi: 10.1111/aas.70096. PubMed 40757745 ↗
  • Aslam TN, Klitgaard TL, Moller MH, Perner A, Hofso K, Skrubbeltrang C, Flaatten HI, Rasmussen BS, Laake JH. Spontaneous versus controlled mechanical ventilation in patients with acute respiratory distress syndrome - Protocol for a scoping review. Acta Anaesthesiol Scand. 2020 Jul;64(6):857-860. doi: 10.1111/aas.13570. Epub 2020 Mar 20. PubMed 32157683 ↗
  • Laake JH, Smastuen MC, Moller MH, Larsson A, Aslam TN, Hofso K, Pham T, Fan E, Bellani G, Laffey JG; LUNG SAFE Investigators. Patient characteristics, management and outcomes in a Nordic subset of the "large observational study to understand the global impact of severe acute respiratory failure" (LUNG SAFE) study. Acta Anaesthesiol Scand. 2022 Jul;66(6):684-695. doi: 10.1111/aas.14069. Epub 2022 May 12. PubMed 35398892 ↗
  • Aslam TN, Klitgaard TL, Hofso K, Rasmussen BS, Laake JH. Spontaneous Versus Controlled Mechanical Ventilation in Patients with Acute Respiratory Distress Syndrome. Curr Anesthesiol Rep. 2021;11(2):85-91. doi: 10.1007/s40140-021-00443-8. Epub 2021 Mar 3. PubMed 33679255 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Mar 11, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Mar 30, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added — first site in Norway
Show site
  • Oslo University Hospital - Rikshospitalet · Oslo, Norway
Oct 15, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Norway
    Show site
    • Oslo University Hospital - Rikshospitalet · Oslo, Norway
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07463885
Collaborators
Copenhagen University Hospital, Rigshospitalet, Aalborg University Hospital
Responsible party
Jon Henrik Laake (Principal Investigator, MD, PhD, Oslo University Hospital) — Principal investigator
First posted
Mar 11, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Jon Henrik Laake, MD, PHD
Contact
jlaake@ous-hf.no
0047 97660919
Tayyba Naz Aslam, MD
Contact
tayasl@ous-hf.no

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion